Developing next generation cell and protein therapeutics for fatal diseases AdAlta (ASX:1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers. AdAlta’s “East to West” cellular immunotherapy strategy is the primary driver of future growth and value creation initiatives. This strategy is seeing the Company […]